Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, strategically investing in early-stage biotech and digital health companies. The firm focuses on transformational science and technology to improve human health, serving as an entry point to the innovation ecosystem for Sanofi. They invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and working alongside portfolio companies to drive long-term value.
Sanofi Ventures
450 Water Street, Cambridge, MA 02141, USA
What We Do
Sanofi Ventures provides strategic investment in early-stage biotech and digital health companies, offering access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization.
Geographic Focus
Portfolio
Curevo is advancing a non-mRNA adjuvanted subunit vaccine for shingles with improved tolerability.
#Biotechnology
Latigo is developing a pipeline of Nav1.8 inhibiting small molecules for both acute and chronic pain.
#Biotechnology
Tisento is developing Zagociguat, a first and best-in-class oral investigational medicine for mitochondrial diseases.
#Biotechnology
Fulcrum is focused on developing small molecules for genetically defined rare diseases, including losmapimod for facioscapulohumeral muscular dystrophy.
#Biopharmaceutical
Evidation captures and analyzes passive, continuous behavior data to quantify health outcomes.
#Digital Health
i2O is developing a platform for oral delivery of traditionally injectable biological drugs.
#Biotechnology
Kymera is developing protein degrader therapies targeting IRAK4 for immune-inflammatory diseases.
#Biotechnology
Aetion delivers real-world evidence for life sciences, payers, providers, and regulatory agencies.
#Healthcare Technology
Science 37 develops decentralized clinical trials using digital technologies to streamline participant recruitment and retention.
#Clinical Research
GlycoMimetics focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs.
#Biotechnology
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding.
#Biotechnology
Granite Bio targets fundamentals of inflammation, autoimmunity, and fibrosis.
#Biotechnology
Icosavax focuses on developing safe and effective vaccines against infectious diseases.
#Biotechnology
Imbria Pharmaceuticals translates understanding of cellular metabolism into innovative medicines.
#Biotechnology
Immune Design activates the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases.
#Biotechnology
Inozyme Pharma develops new medicines to treat rare disorders of calcification.
#Biotechnology
LAVA Therapeutics develops a proprietary bispecific antibody platform that engages gamma-delta T cells.
#Biotechnology
Lumena Pharmaceuticals is dedicated to providing better treatment options for rare and debilitating liver diseases and serious metabolic disorders.
#Biotechnology
Lysosomal Therapeutics is dedicated to innovative small molecule research and development in the field of neurodegeneration.
#Biotechnology
MacroGenics focuses on discovering and developing innovative monoclonal antibody-based therapeutics.
#Biotechnology
Matchpoint is harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses.
#Biotechnology
Medisafe delivers a next-generation patient engagement and medication adherence solution.
#Digital Health
Mirador is a next-generation precision medicine company focused on immunology and inflammation.
#Biotechnology
Muna Therapeutics discovers and develops therapies that slow or stop devastating neurodegenerative diseases.
#Biotechnology
Navitor is pioneering the selective targeting of mTORC1 activation to develop a new class of medicines for age-related diseases.
#Biotechnology
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.
#Biotechnology
NodThera is developing a new class of potent and selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation.
#Biotechnology
Normunity is identifying and targeting novel mechanisms to remove cancer's barriers to normal immunity.
#Biotechnology
Nura Bio is developing neuroprotective therapies for the treatment of a broad range of neurological diseases.
#Biotechnology
Nuvig Therapeutics is developing a first-in-class Fc fragment immunomodulator aimed at improving autoimmune dysregulation without suppressing the immune system.
#Biotechnology
Odyssey is advancing a pipeline of potential first and best in class immunology and oncology programs.
#Biotechnology
Omada Health is a digital behavioral medicine company that inspires and enables people to change the habits that put them most at risk for chronic conditions.
#Digital Health
OMass Therapeutics is identifying new medicines using novel biochemistry techniques, native mass spectrometry and custom chemistry.
#Biotechnology
Ovid Therapeutics is committed to transforming the lives of patients with rare and orphan diseases of the brain.
#Biotechnology
Proteostasis Therapeutics is developing disease-modifying therapeutics for diseases of protein processing.
#Biotechnology
QurAlis is a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
#Biotechnology
ReCode Therapeutics is developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver.
#Biotechnology
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
#Biotechnology
Selecta is developing immune modulating nanomedicines that enable novel biologic therapies by preventing harmful immune responses.
#Biotechnology
T-Therapeutics is developing next generation TCR therapeutics to transform cancer treatment.
#Biotechnology
Therini Bio is focusing on developing novel therapies based on a deep understanding of fibrin.
#Biotechnology
Ultragenyx is committed to bringing to market life-transforming therapeutics for patients with rare and ultra-rare metabolic genetic diseases.
#Biotechnology
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body's own immune system to fight cancer.
#Biotechnology
Veralox Therapeutics Inc is developing first-in-class therapeutics targeting 12-Lipoxygenase (12-LOX) to bring new treatments to patients with rare blood disorders and diabetes.
#Biotechnology
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment.
#Digital Health
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding.
#Biotechnology